Clinical trials: Adalimumab, active
Adult Non-infectious Uveitis
A Multicenter, Open-label Study on the Efficacy and Safety of Tebiovio® (Adalimumab) in Treating Chinese Children With Severe Plaque Psoriasis
This study is a real-world clinical research on adalimumab. The project plans to enroll 30 subjects. The safety and efficacy of adalimumab injection for adult non-infectious uveitis are being investigated.
- Trial name
- NCT07663331
- Testing
- TyboWe® Adalimumab Injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Rheumatoid Arthritis
Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response
Rheumatoid arthritis (RA) is a common disease with approximately 1% prevalence. RA is also a chronic, progressive disease with no cure.
- Trial name
- NCT03414502
- Testing
- Methotrexate, Abatacept, Adalimumab
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- University of Nebraska
Psoriatic Arthritis, Ultrasound Assessment
Apremilast and Adalimumab in Psoriatic Arthritis Patients
The aim of this work is to compare the efficacy of Apremilast combined with Methotrexate versus Adalimumab combined with Methotrexate
- Conditions
- Psoriatic Arthritis, Ultrasound Assessment, TNF
- Trial name
- NCT07398651
- Testing
- Adalimumab, Apremilast
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Tanta University
Juvenile Psoriatic Arthritis
A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
Psoriatic arthritis (PsA) is a type of arthritis that happens when the body's immune system attacks healthy cells and tissues causing joint pain, stiffness, and swelling. Symptoms can get worse and go away for periods of time.
- Trial name
- NCT06100744
- Testing
- Adalimumab, Risankizumab
- Where
- 34 sites in United States, Australia and 7 more
- Volunteers
- 40 people
- Sponsor
- AbbVie
Crohn Disease
Prospective Cohort Establishment and Clinical Observation of Children With Crohn's Disease
To evaluate the clinical manifestations, treatment options, and improved clinical outcomeof children with Crohn's disease in real-world Settings: (1) analysis of clinical manifestations; (2) probability of using the same…
- Trial name
- CD (NCT06673134)
- Testing
- enteral nutrition, Immunotherapy, biological agents
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Tongji Hospital
Esophageal Squamous Cell Carcinoma (ESCC)
Adebrelimab Combined With Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Carcinoma
This study aims to systematically evaluate the safety and efficacy of adalimumab combined with paclitaxel, carboplatin, and short-course radiotherapy in the neoadjuvant treatment of esophageal squamous cell carcinoma.
- Trial name
- ANCRE (NCT07595770)
- Testing
- • Adebrelimab and nab-paclitaxel, carboplatin in Combination With radiotherapy
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Crohn Disease
Efficacy and Safety of CDED With Anti-TNF-α Biologics in Crohn's Disease
Crohn's disease (CD) is a chronic inflammatory bowel disease with high recurrence and surgical rates. Mucosal healing is a key therapeutic goal, yet current anti-TNF-α biologics achieve only about 30% mucosal healing.
- Trial name
- CDED (NCT07344428)
- Testing
- Crohn's Disease Exclusion Diet
- Where
- China
- Volunteers
- 185 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Type 1 Diabetes, New Onset
A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes
This multi-center randomized controlled trial will assess the safety and efficacy of ATG followed by either adalimumab or verapamil in preserving insulin secretion 2 years from randomization in persons aged 9 to <21 with…
- Trial name
- WAVE T1D (NCT07061574)
- Testing
- Anti-thymocyte globulin (ATG), verapamil extended-release capsule, Adalimumab
- Where
- 11 sites in United States
- Volunteers
- 120 people
- Sponsor
- City of Hope Medical Center
Juvenile Idiopathic Arthritis Associated Uveitis, Uveitis, Anterior
Adalimumab Dose Adjustment for Pediatric Uveitis Treatment Trial
The goal of this clinical trial is to learn whether children and young adults with well-controlled juvenile idiopathic arthritis (JIA)-associated uveitis or chronic anterior uveitis can safely take adalimumab (or biosimilar)…
- Trial name
- ADAPT (NCT07699107)
- Testing
- Adalimumab/Biosimilar
- Where
- 18 sites in United States, Italy and 1 more
- Volunteers
- 160 people
- Sponsor
- Nisha Acharya
Rheumatoid Arthritis, Ankylosing Spondylitis
Korean College of Rheumatology Biologics and Targeted Therapy Registry
We established a nationwide biologics and targeted synthetic DMARDs registry (in the form of an inception cohort) to study the safety profiles in rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis patients…
- Conditions
- Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis
- Trial name
- KOBIO (NCT01965132)
- Testing
- Biologic or targeted synthetic DMARD
- Where
- South Korea
- Volunteers
- 10,000 people
- Sponsor
- Seoul National University Hospital
Pancreatic Cancer
AG Followed by FOLFIRINOX Both Combined With PD-L1 Antibodies as a Conversion Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer.
The goal of this interventional study is to learn about the clinical efficacy of sequential therapy (albumin paclitaxel, gemcitabine combined with PD-L1 antibodies, followed by liposomal irinotecan, oxaliplatin and 5-FU/LV…
- Trial name
- ZSPAC-14 (NCT07208539)
- Testing
- Treatment: AG & anti-PD-L1 + FOLFIRINOX & anti-PD-L1
- Volunteers
- 77 people
- Sponsor
- Shanghai Zhongshan Hospital
Rectal Cancers
Neoadjuvant Radiotherapy Combined With NALIRIFOX and Adebrelimab in pMMR/MSS Locally Advanced Rectal Cancer: A Prospective, Randomized, Phase II Clinical Trial
To explore the efficacy and safety of radiotherapy combined with Adebrelimab and NALIRIFOX in patients with pMMR/MSS locally advanced rectal cancer
- Trial name
- NCT07622771
- Testing
- Adalimumab+NALIRIFOX→Short course radiotherapy →Adalimumab+NALIRIFOX, Adalimumab+NALIRIFOX→Long course chemoradiotherapy →Adalimumab+NALIRIFOX
- Where
- China
- Volunteers
- 84 people
- Sponsor
- Sun Yat-sen University
Takayasu Arteritis
Biologic Treatment Withdrawal in Takayasu Arteritis Patients in Sustained Remission
Takayasu arteritis is a chronic large-vessel vasculitis affecting the aorta and its major branches. Biologic therapies such as tumor necrosis factor inhibitors and tocilizumab are commonly used in patients with refractory or…
- Trial name
- NCT07491913
- Testing
- Tociliuzumab, Infliximab, Adalimumab
- Where
- Turkey (Türkiye)
- Volunteers
- 40 people
- Sponsor
- Marmara University
Hidradenitis Suppurativa (HS)
MAIT Cells in Hidradenitis Suppurativa
Hidradenitis Suppurativa (HS) is a chronic, debilitating inflammatory skin disease characterized by painful, purulent lesions primarily in skin folds. Its pathogenesis remains poorly understood.
- Trial name
- HS-MAIT (NCT07388446)
- Testing
- Collect lesional biopsies, Collect score from Bristol stool scale
- Where
- France
- Volunteers
- 45 people
- Sponsor
- Hospices Civils de Lyon
Psoriasis, Psoriasis Arthritis
A Multi-center RCT Clinical Trial on Personalized Precision Medicine for Patients With Psoriasis and Psoriatic Arthritis and Investigation on Cardiovascular Biomarkers
The inclusion criteria for this study were patients aged 18 to 75 years with a confirmed diagnosis of psoriasis by a dermatologist or psoriatic arthritis by a rheumatologist.
- Conditions
- Psoriasis, Psoriasis Arthritis, Biologics
- Trial name
- SMILE (NCT07149792)
- Testing
- Prescreen platform, biologics treatment
- Where
- 2 sites in Taiwan
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Taichung Veterans General Hospital
Oral Squamous Cell Carcinoma (OSCC), Neoadjuvant Chemoimmunotherapy
Adebrelimab Combined With Carboplatin and Albumin-bound Taxanol in the Treatment of Resectable Locally Advanced Oral Squamous Cell Carcinoma Cardiac, Randomized, Phase II Exploratory Study
Neoadjuvant immunochemotherapy can effectively increase the postoperative pathological complete response rate, improve the survival rate of patients, and reduce the risk of recurrence in oral squamous cell carcinoma (OSCC).
- Trial name
- NCT07137858
- Testing
- Preoperative neoadjuvant immunotherapy chemotherapy, Two courses of preoperative neoadjuvant immunotherapy chemotherapy, Three courses of preoperative neoadjuvant immunotherapy chemotherapy
- Volunteers
- 70 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Crohn Disease (CD)
TNFi Plus Low-Dose Upadacitinib vs TNFi Intensification in Crohn's Disease With Suboptimal Response
This multicenter, randomized, controlled trial aims to evaluate the efficacy and safety of standard-dose tumor necrosis factor inhibitor (TNFi) plus low-dose upadacitinib compared with TNFi dose intensification in patients with…
- Trial name
- CD (NCT07510191)
- Testing
- Upadacitinib, Infliximab Dose Intensification, Adalimumab Dose Intensification
- Where
- China
- Volunteers
- 312 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Crohn's Disease
Comparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration.
A substantial fraction of IBD patients with an initial response to infliximab or adalimumab later experience re-emerging active disease despite ongoing anti-Tumour Necrosis Factor (TNF) agents maintenance therapy.
- Trial name
- VEDIAN (NCT06180382)
- Testing
- Adalimumab, Vedolizumab
- Where
- 12 sites in France
- Volunteers
- 220 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Inflamatory Bowel Disease, Crohn Disease (CD)
Comparison of the Efficacy of Different Biologic Agents in Preventing Postoperative Endoscopic Recurrence of Crohn's Disease
This retrospective cohort study aims to compare the efficacy of different biologics in preventing postoperative endoscopic recurrence in Crohn's disease (CD).
- Trial name
- NCT07694674
- Testing
- Infliximab, Adalimumab, Vedolizumab
- Where
- China
- Volunteers
- 198 people
- Sponsor
- Shanghai 10th People's Hospital
Skin Inflammation, Allergic Contact Dermatitis
Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation
The purpose of this study is to answer: how do inflammation and anti-inflammatory skin therapies work in the skin? Inflammation is a protective response from the body's immune system to injury, disease, or irritation.
- Trial name
- NCT05535738
- Testing
- Squaric Acid Dibutyl Ester, Known patch test allergens, Dupilumab
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Wei-Che Ko